Canó’s PED Suspension Has a Silver Lining for Mets
Not too long ago, Robinson Canó appeared to have a real shot at becoming the first second baseman to reach the twin milestones of 3,000 hits and 400 home runs, as well as an eventual berth in the Hall of Fame. In May 2018, however, while playing for the Mariners, he drew an 80-game suspension after testing positive for a banned diuretic. Now, as a member of the Mets following a blockbuster trade that has thus far looked like a flop, he’s drawn another suspension for violating the game’s joint drug agreement. As his second offense, this one will cost him the entire 2021 season as well as all of his $24 million salary. That’s a situation that could benefit the Mets, who under new owner Steve Cohen are already primed to be one of the winter’s more aggressive teams.
It’s the latest bum note for Canó in his second tour of New York. Acquired from the Mariners on December 3, 2018 along with Edwin Díaz and cash in exchange for a five-player package headlined by first-round picks Jarred Kelenic and Justin Dunn, the former Yankees star was limited to 107 games due to hamstring and quad injuries in 2019. Both his 93 wRC+ and 0.8 WAR represented his worst numbers since 2008, and the deal looked even worse due to Díaz’s collapse; the pair’s underperformance probably cost the Mets a Wild Card berth, as they finished with 86 wins, three fewer than the lower Wild Card seed, the Brewers. Adding insult to injury, Eric Longenhagen placed Kelenic 11th on his Top 100 Prospects list in the spring, the same ranking that both Baseball America, and MLB.com gave him.
Canó did fare better in 2020. Though he served a 10-day stint on the Injured List due to a groin strain in early August, he hit .316/.352/.544 while tying for second on the team with 10 homers, and placing fourth via both his 141 wRC+ and 1.3 WAR. It wasn’t nearly enough to help the Mets, who sputtered to a 26-34 record and a fourth-place finish in the NL East. Read the rest of this entry »


